Modulators of Response to Tumor Necrosis-Related Apoptosis-Inducing Ligand (TRAIL) Therapy in Ovarian Cancer
Abstract
Ovarian Cancer is the leading cause of death from gynecologic cancers in the developed world. We have previously identified a homeobox gene, Six1, which is overexpressed in ovarian cancers as compared to normal ovarian surface epithelium. Overexpression of Six1 is associated with resistance to Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) based therapies. We have discovered that this resistance in ovarian cancers is likely related to over-expression of the TRAIL decoy receptor DcR2. On-going studies are evaluating the mechanism and significance of this finding on the way to designing new treatments for ovarian cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2009
- Accession Number
- ADA508266
Entities
People
- Kian Behbakht
Organizations
- University of Colorado Health